Free Trial

Pfizer, BioNTech seek EU's OK to use COVID vaccine on kids

In this March 27, 2021 file photo a laboratory worker simulates the workflow in a cleanroom of the BioNTech Corona vaccine production in Marburg, Germany, during a media day. Ugur Sahin, BioNTech's chief executive, which developed the first widely approved COVID-19 vaccine with U.S. partner Pfizer, said Europe can achieve 'herd immunity' against the coronavirus within the next four months. (AP Photo/Michael Probst, file)

LONDON (AP) — Pfizer Inc. and BioNTech have submitted a request to the European drug regulator for the approval of their coronavirus vaccine to be extended to include children 12 to 15 years old, in a move that could offer younger and less at-risk populations in Europe access to the shot for the first time.

In a statement Friday, the two pharmaceuticals said their submission to the European Medicines Agency is based on an advanced study in more than 2,000 adolescents that showed their vaccine to be safe and effective. The children will continue to be monitored for longer-term protection and safety for another two years.

BioNTech and Pfizer have previously requested their emergency use authorization with the U.S. Food and Drug Administration also be extended to children 12 to 15 years old.

German Health Minister Jens Spahn welcomed the news that the vaccine might soon get the green light for older children.

“This can make a further real difference to our vaccine campaign, if approval is granted,” he said on the sidelines of a visit to a vaccine manufacturing plant in the German town of Reinbek.

Most COVID-19 vaccines being rolled out worldwide are for adults, who are at higher risk from the coronavirus. But vaccinating children of all ages will be critical to stopping the pandemic, especially since some research has shown that older children may play a role in spreading the virus.

Children represent about 13% of COVID-19 cases documented in the U.S. And while children are far less likely than adults to get seriously ill, at least 268 have died from COVID-19 in the U.S. alone and more than 13,500 have been hospitalized, according to a tally by the American Academy of Pediatrics. That’s more than die from the flu in an average year. A small number have also developed a serious inflammatory condition linked to the coronavirus.

Immunizing children against COVID-19 might also give authorities more confidence in reopening schools, since getting children to comply with physical distancing and mask-wearing has sometimes been challenging.

Other COVID-19 vaccine manufacturers including AstraZeneca, Moderna and Johnson & Johnson are also studying whether their shots can safely be used in children.

The COVID-19 vaccine made by Pfizer and BioNTech was the first one to be granted a greenlight by the EMA last December, when it was licensed for anyone 16 and over across the 27-nation EU bloc.

___

Frank Jordans in Berlin contributed to this report.

— Follow more of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.9624 of 5 stars
$155.39+0.6%3.19%22.49Moderate Buy$175.94
Pfizer (PFE)
4.9993 of 5 stars
$25.83+0.2%6.50%34.91Moderate Buy$32.92
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Netflix’s Bold Moves: 4 Strategies for Explosive Growth

Netflix’s Bold Moves: 4 Strategies for Explosive Growth

Netflix is shaking up the streaming world again with its new ad-supported tier, leading to a surge in subscribers and revenue.

Recent Videos

Small Caps, Financials & Bitcoin Lead the Rising Bull Market: Chris Rowe’s Top Picks
MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs
How Abacus Life is Transforming Life Insurance into Assets | MarketBeat CEO Series

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines